source
- Evaxion drops solid tumor vaccine program to prioritize brain cancer vaccine candidateEvaxion Biotech announced it has discontinued development of its next‑generation solid tumor vaccine, EVX‑03, and will redirect resources toward a brain cancer vaccine candidate developed with Duke…
- Silence Therapeutics' Phase 2 trial shows strong results for divesiran in polycythemia vera, shares jump 30%Silence Therapeutics reported that its nucleic‑acid drug divesiran achieved a 69% placebo‑adjusted response rate in a Phase 2 study of polycythemia vera patients. Safety was reported as clean, with…